On July 28, 2006, Jeffrey Kindler was appointed by the board of directors as Henry A. McKinnell Jr.'s successor, making him the chief executive officer. Later in the year, he was also selected to serve as a chairman. This is in spite of his lack of pharmaceutical experience, instead, Kindler offered Pfizer his legal expertise as a tenured lawyer. Known for his controversial support of Obama Care and various acts of kindness, Kindler shocked the company by retiring unexpectedly from Pfizer in 2010. He later went on to become the CEO of a biotechnology company called Centrexion Corp., which focusses on pain management. He continues to play a role in public and private companies, serving as a board member. Perhaps ironically, he was elected to the board of directors of The National Center on Addiction and Substance Abuse at Columbia University. Perhaps the retirement was not as unexpected as originally thought. The stock price of Pfizer had tumbled from $49 to $17 and the company has some internal turmoil, particularly with--or alongside--Mary McLeod, who was leading a team of demoralized individuals who had given her a rather low rating of her job performance, earning her 1-2 out of 5 in some rather important aspects of her leadership. Unconfirmed rumors surrounded his inability to lead his subordinates in a healthy way, causing Ian Read and Amy Shulman to threaten their own resignation from the company. According to Fortune, his temperament was labile as was his decision making, making the work environment one of walking on eggshells. Without any solid answers or proof, his reasons for leaving remain only what he had reported himself, that the 24/7 nature of the job had "made this period extremely demanding on [him]."